On 2 October 2024, South Korea-headquartered ABL Bio announced it has entered a clinical collaboration and supply agreement with MSD to evaluate the bispecific antibody ABL 103 in combination with MSD’s Keytruda® (pembrolizumab) in patients with advanced or metastatic solid tumours.
ABL 103, a bispecific antibody which targets the tumour-associated antigen B7-H4 and the costimulatory receptor 4-1BB, is currently in a phase 1 clinical trial in South Korea. It will be evaluated with Keytruda® in a Phase 1b/2 clinical trial
On 12 September 2024, MSD’s Keytruda® was approved in Canada as monotherapy for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and which have no satisfactory alternative treatment options.